The Blood and Marrow Transplant (BMT) Program team performed 167 blood and marrow/stem cell/umbilical cord blood transplants in 2011. We performed 46 autologous transplants for non-Hodgkin lymphoma and 54 for multiple myeloma amyloidosis.
The most common disease indication for transplantation was myeloma/amyloidosis. This was followed by non-Hodgkin lymphoma, and Hodgkin's disease.
Our 100-day survival rate for autologous transplantation was 100 percent. Our 100-day survival rate for related ablative allogeneic transplantation was 100 percent.
National Marrow Donor Program
Our program has been an NMDP transplant center since December 1988. These statistics can help you understand the differences among transplant centers.
Blood and Marrow Transplant Program
Progenitor Cell Processing Laboratory
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.